argenex SE (NASDAQ:ARGX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of argenex SE (NASDAQ:ARGX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-three brokerages that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $879.2778.

• 3 Healthcare Pathbreakers With Long-Term Tailwinds

ARGX has been the subject of a number of research reports. Piper Sandler raised their price objective on argenex from $820.00 to $930.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of argenex in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of argenex from a "hold" rating to a "buy" rating in a research note on Friday, October 3rd. Truist Financial increased their price objective on shares of argenex from $700.00 to $918.00 and gave the company a "buy" rating in a research note on Monday, September 15th. Finally, Bank of America raised their price objective on shares of argenex from $880.00 to $887.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd.

Get Our Latest Stock Analysis on argenex

argenex Price Performance

• 5 medical stocks growing earnings by triple digits

NASDAQ ARGX opened at $889.89 on Thursday. The company's fifty day moving average is $793.04 and its two-hundred day moving average is $668.78. argenex has a 52-week low of $510.05 and a 52-week high of $907.47. The firm has a market capitalization of $54.79 billion, a price-to-earnings ratio of 38.21, a P/E/G ratio of 0.91 and a beta of 0.45.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating analysts' consensus estimates of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The business had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.07 billion. As a group, sell-side analysts expect that argenex will post 3.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On argenex

• Argenx's 28% Surge & Promising Product Propel Investor Confidence

Several large investors have recently modified their holdings of the stock. WPG Advisers LLC bought a new position in shares of argenex during the 1st quarter worth approximately $37,000. Bessemer Group Inc. grew its position in argenex by 276.5% in the third quarter. Bessemer Group Inc. now owns 64 shares of the company's stock valued at $47,000 after acquiring an additional 47 shares during the period. Mather Group LLC. acquired a new stake in shares of argenex during the 3rd quarter worth about $50,000. Rossby Financial LCC grew its stake in argenex by 115.2% during the third quarter. Rossby Financial LCC now owns 71 shares of the company's stock worth $54,000 after buying an additional 38 shares during the last quarter. Finally, Brooklyn Investment Group grew its stake in argenex by 102.7% during the first quarter. Brooklyn Investment Group now owns 75 shares of the company's stock worth $44,000 after buying an additional 38 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Featured Stories

• Five stocks we like better than argenex
• 3 Best Fintech Stocks for a Portfolio Boost
• Rare Earth Stocks: The Truce That Isn't a Truce
• What Do S&P 500 Stocks Tell Investors About the Market?
• Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
• What Investors Need to Know About Upcoming IPOs
• C3.ai's Reset: Why New Leadership Could Spark a Turnaround

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in argenex Right Now?

Before you consider argenex, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenex wasn't on the list.

While argenex currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here